HMGCR gene polymorphism is associated with stroke risk in the EPIC-Norfolk study

European Journal of Preventive Cardiology

Volumn 17, Issue 1, 2010, Pages 89-93

  Freitas, Renata N ^a,b   Khaw, Kay Tee ^b,c   Wu, Kelvin ^d   Bowman, Richard ^d   Jeffery, Hannah ^d   Luben, Robert ^c   Wareham, Nick J ^c,e   Rodwell, Sheila ^b,c,d  

^a FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^b MRC Centre for Nutritional Epidemiology in Cancer Prevention and Survival   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e MRC EPIDEMIOLOGY UNIT   (United Kingdom)

Author keywords

HMGCR polymorphism; hypertension; stroke risk

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE;

ADULT; AGED; ALLELE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PYROSEQUENCING; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE; SYSTOLIC BLOOD PRESSURE;

AGED; BLOOD PRESSURE; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; ENGLAND; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYPERTENSION; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE; TIME FACTORS;

EID: 77149124920     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/HJR.0b013e328330be77     Document Type: Article

References (37)

1. World Health Organization. The global burden of disease: 2004 update. Geneva, Switzerland: WHO Press; 2008.
2. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet 2008; 371: 1612–1623.
3. Leys D, Deplanque D, Mounier-Vehier C, kowiak-Cordoliani MA, Lucas C, Bordet R. Stroke prevention: management of modifiable vascular risk factors. J Neurol 2002; 249: 507–517.
4. Myint PK, Sinha S, Luben RN, Bingham SA, Wareham NJ, Khaw KT. Risk factors for first-ever stroke in the EPIC-Norfolk prospective population-based study. Eur J Cardiovasc Prev Rehabil 2008; 15: 663–669.
5. Amarenco P, Lavallee P, Touboul PJ. Stroke prevention, blood cholesterol, and statins. Lancet Neurol 2004; 3: 271–278.
6. Paciaroni M, Hennerici M, Agnelli G, Bogousslavsky J. Statins and stroke prevention. Cerebrovasc Dis 2007; 24: 170–182.
7. März W, Köenig W. HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering? Eur J Cardiovasc Prev Rehabil 2003; 10: 169–179.
8. Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP Jr, Ridker PM. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 2004; 291: 2821–2827.
9. Leitersdorf E, Luskey KL. HgiAI polymorphism near the HMGCR promoter. Nucleic Acids Res 1990; 18: 5584.
10. Leitersdorf E, Hwang M, Luskey KL. ScrFI polymorphism in the 2nd intron of the HMGCR gene. Nucleic Acids Res 1990; 18: 5584.
11. Zuliani G, Hobbs HH. A high frequency of length polymorphism in repeated sequences adjacent to alu sequences. Am J Hum Genet 2008; 46: 963–969.
12. Hubacek JA, Pistulkova H, Valenta Z, Poledne R. (TTA)n repeat polymorphism in the HMG-CoA reductase gene and cholesterolaemia. Vasa 1999; 28: 169–171.
13. Plat J, Mensink RP. Relationship of genetic variation in genes encoding apolipoprotein A-IV, scavenger receptor BI, HMG-CoA reductase, CETP and apolipoprotein E with cholesterol metabolism and the response to plant stanol ester consumption. Eur J Clin Invest 2002; 32: 242–250.
14. Singer JB, Holdaas H, Jardine AG, Fellstrom B, Os I, Bermann G, et al. Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. J Lipid Res 2007; 48: 2072–2078.
15. Tong Y, Zhang S, Li H, Su Z, Kong X, Liu H, et al. 8302A/C and (TTA)n polymorphisms in the HMG-CoA reductase gene may be associated with some plasma lipid metabolic phenotypes in patients with coronary heart disease. Lipids 2004; 39: 239–241.
16. Hindorff LA, Lemaitre RN, Smith NL, Bis JC, Marciante KD, Rice KM, et al. Common genetic variation in six lipid-related and statin-related genes, statin use and risk of incident nonfatal myocardial infarction and stroke. Pharmacogenet Genomics 2008; 18: 677–682.
17. Khaw KT, Bingham S, Welch A, Luben R, O'Brien E, Wareham N, et al. Blood pressure and urinary sodium in men and women: the Norfolk Cohort of the European Prospective Investigation into Cancer (EPIC-Norfolk). Am J Clin Nutr 2004; 80: 1397–1403.
18. Wareham NJ, Jakes RW, Rennie KL, Schuit J, Mitchell J, Hennings S, et al. Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Public Health Nutr 2003; 6: 407–413.
19. Day N, Oakes S, Luben R, Khaw KT, Bingham S, Welch A, et al. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer 1999; 80: 95–103.
20. Wu K, Bowman R, Welch AA, Luben RN, Wareham N, Khaw KT, et al. Apolipoprotein E polymorphisms, dietary fat and fibre, and serum lipids: the EPIC Norfolk study. Eur Heart J 2007; 28: 2930–2936.
21. Bingham S, Luben R, Welch A, Low YL, Khaw KT, Wareham N, et al. Associations between dietary methods and biomarkers, and between fruits and vegetables and risk of ischaemic heart disease, in the EPIC Norfolk Cohort Study. Int J Epidemiol 2008; 37: 978–987.
22. Freitas RN, Khaw KT, Wu K, Bowman R, Jeffery H, Luben R, et al. A HMGCR polymorphism is associated with relations between blood pressure and urinary sodium and potassium ratio in the EPIC-Norfolk study. J Am Soc Hypertens 2009; 3: 238–244.
23. Polisecki E, Muallem H, Maeda N, Peter I, Robertson M, McMahon AD, et al. Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. Atherosclerosis 2008; 200: 109–114.
24. Markus HS, Alberts MJ. Update on genetics of stroke and cerebrovascular disease 2005. Stroke 2006; 37: 288–290.
25. Schulz UGR, Flossmann E, Rothwell PM. Heritability of ischemic stroke in relation to age, vascular risk factors, and subtypes of incident stroke in population-based studies. Stroke 2004; 35: 819–824.
26. Flossmann E, Schulz UGR, Rothwell PM. Systematic review of methods and results of studies of the genetic epidemiology of ischemic stroke. Stroke 2004; 35: 212–227.
27. Jerrard-Dunne P, Cloud G, Hassan A, Markus HS. Evaluating the genetic component of ischemic stroke subtypes: a family history study. Stroke 2003; 34: 1364–1369.
28. Alberts MJ. Genetics of cerebrovascular disease. Stroke 2004; 35: 342–344.
29. Gretarsdottir S, Thorleifsson G, Reynisdottir ST, Manolescu A, Jonsdottir S, Jonsdottir T, et al. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat Genet 2003; 35: 131–138.
30. Enquobahrie DA, Smith NL, Bis JC, Carty CL, Rice KM, Lumley T, et al. Cholesterol ester transfer protein, interleukin-8, peroxisome proliferator activator receptor alpha, and Toll-like receptor 4 genetic variations and risk of incident nonfatal myocardial infarction and ischemic stroke. Am J Cardiol 2008; 101: 1683–1688.
31. Marciante KD, Totah RA, Heckbert SR, Smith NL, Lemaitre RN, Lumley T, et al. Common variation in cytochrome P450 epoxygenase genes and the risk of incident nonfatal myocardial infarction and ischemic stroke. Pharmacogenet Genomics 2008; 18: 535–543.
32. Lemaitre RN, Heckbert SR, Sotoodehnia N, Bis JC, Smith NL, Marciante KD, et al. Beta1-and beta2-adrenergic receptor gene variation, beta-blocker use and risk of myocardial infarction and stroke. Am J Hypertens 2008; 21: 290–296.
33. Ezzati M, Lopez AD, Rodgers A, Vander HS, Murray CJ. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360: 1347–1360.
34. Beckett NS. Prevention of stroke. Eur J Cardiovasc Prev Rehabil 2001; 8: 257–264.
35. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–1913.
36. Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A. Non-lipid-related effects of statins. Ann Med 2000; 32: 164–176.
37. Sinha S, Myint PK, Luben RN, Khaw KT. Accuracy of death certification and hospital record linkage for identification of incident stroke. BMC Med Res Methodol 2008; 8: 74.